Latest Insider Transactions at Recursion Pharmaceuticals, Inc. (RXRX)
This section provides a real-time view of insider transactions for Recursion Pharmaceuticals, Inc. (RXRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of RECURSION PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of RECURSION PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 12
2023
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
31,818
-0.85%
|
$381,816
$12.35 P/Share
|
|
Jul 12
2023
|
Christopher Gibson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
31,250
+3.19%
|
$62,500
$2.48 P/Share
|
|
Jul 11
2023
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
8,885
-0.12%
|
$53,310
$6.89 P/Share
|
|
Jul 03
2023
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,609
+0.25%
|
-
|
|
Jul 03
2023
|
R. Martin Chavez Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,541
+4.53%
|
-
|
|
Jul 03
2023
|
Zavain Dar Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,863
+2.52%
|
-
|
|
Jul 03
2023
|
Zachary Bogue Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,440
+13.31%
|
-
|
|
Jun 29
2023
|
Blake Borgeson Director |
SELL
Bona fide gift
|
Direct |
14,000
-0.19%
|
-
|
|
Jun 29
2023
|
Tina Marriott Larson President and COO |
SELL
Open market or private sale
|
Direct |
3,000
-0.7%
|
$21,000
$7.49 P/Share
|
|
Jun 29
2023
|
Tina Marriott Larson President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+0.7%
|
$3,000
$1.06 P/Share
|
|
Jun 27
2023
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
8,885
-0.12%
|
$62,195
$7.39 P/Share
|
|
Jun 16
2023
|
Blake Borgeson Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,612
+0.17%
|
-
|
|
Jun 16
2023
|
Robert Hershberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,612
+24.62%
|
-
|
|
Jun 16
2023
|
Zavain Dar Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,612
+15.23%
|
-
|
|
Jun 16
2023
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,612
+1.94%
|
-
|
|
Jun 16
2023
|
R. Martin Chavez Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,612
+19.82%
|
-
|
|
Jun 16
2023
|
Terry Ann Burrell Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,612
+6.84%
|
-
|
|
Jun 16
2023
|
Shafique Virani Chief Business Officer |
SELL
Open market or private sale
|
Direct |
30,000
-17.25%
|
$270,000
$9.41 P/Share
|
|
Jun 16
2023
|
Shafique Virani Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+14.71%
|
$60,000
$2.22 P/Share
|
|
Jun 15
2023
|
Shafique Virani Chief Business Officer |
SELL
Open market or private sale
|
Direct |
30,000
-17.25%
|
$270,000
$9.67 P/Share
|
|
Jun 15
2023
|
Shafique Virani Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+14.71%
|
$60,000
$2.22 P/Share
|
|
Jun 15
2023
|
Christopher Gibson Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
10,000
-1.08%
|
-
|
|
Jun 15
2023
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
10,000
+1.07%
|
-
|
|
Jun 14
2023
|
Michael Secora Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
25,000
-2.97%
|
$250,000
$10.07 P/Share
|
|
Jun 14
2023
|
Michael Secora Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,500
+4.26%
|
$75,000
$2.22 P/Share
|
|
Jun 13
2023
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
15,485
-0.21%
|
$139,365
$9.98 P/Share
|
|
Jun 13
2023
|
Michael Secora Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
25,000
-3.01%
|
$225,000
$9.93 P/Share
|
|
Jun 13
2023
|
Michael Secora Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,500
+4.32%
|
$75,000
$2.22 P/Share
|
|
Jun 07
2023
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
56,436
-5.8%
|
$507,924
$9.05 P/Share
|
|
Jun 07
2023
|
Christopher Gibson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
31,250
+3.11%
|
$62,500
$2.48 P/Share
|
|
Jun 02
2023
|
Shafique Virani Chief Business Officer |
SELL
Open market or private sale
|
Direct |
17,865
-11.04%
|
$142,920
$8.93 P/Share
|
|
Jun 01
2023
|
David J Mauro Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
190,713
+50.0%
|
-
|
|
Jun 01
2023
|
Shafique Virani Chief Business Officer |
SELL
Open market or private sale
|
Direct |
25,000
-13.38%
|
$200,000
$8.58 P/Share
|
|
May 31
2023
|
Tina Marriott Larson President and COO |
SELL
Open market or private sale
|
Direct |
3,000
-0.7%
|
$24,000
$8.63 P/Share
|
|
May 31
2023
|
Tina Marriott Larson President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+0.7%
|
$3,000
$1.06 P/Share
|
|
May 30
2023
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
8,885
-0.12%
|
$71,080
$8.79 P/Share
|
|
May 16
2023
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
8,885
-0.12%
|
$44,425
$5.09 P/Share
|
|
May 15
2023
|
Shafique Virani Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,230
-1.19%
|
$11,150
$5.6 P/Share
|
|
May 15
2023
|
Christopher Gibson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,661
-1.22%
|
$58,305
$5.6 P/Share
|
|
May 15
2023
|
Michael Secora Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,760
-0.6%
|
$23,800
$5.6 P/Share
|
|
May 15
2023
|
Tina Marriott Larson President and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,415
-1.27%
|
$27,075
$5.6 P/Share
|
|
May 03
2023
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
25,000
-100.0%
|
$100,000
$4.91 P/Share
|
|
May 03
2023
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
25,000
+50.0%
|
-
|
|
May 03
2023
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
33,073
-3.35%
|
$132,292
$4.71 P/Share
|
|
May 03
2023
|
Christopher Gibson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
31,250
+3.07%
|
$62,500
$2.48 P/Share
|
|
May 03
2023
|
Christopher Gibson Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
10,000
-0.52%
|
-
|
|
May 03
2023
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
1,338
+0.14%
|
-
|
|
Apr 21
2023
|
Dean Y Li Director |
SELL
Bona fide gift
|
Indirect |
627,705
-100.0%
|
-
|
|
Apr 18
2023
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
8,885
-0.12%
|
$44,425
$5.93 P/Share
|
|
Apr 06
2023
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
40,000
-4.23%
|
$240,000
$6.64 P/Share
|